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Abstract Variant CCN proteins have been identified over
the past decade in several normal and pathological
situations. The production of CCN truncated proteins have
been reported in the case of CCN2(ctgf), CCN3(nov),
CCN4(wisp-1) and CCN6(wisp-3). Furthermore, the natu-
ral CCN5 is known to miss the C-terminal domain that is
present in all other members of the CCN family of proteins.
In spite of compelling evidence that assign important
biological activities to these truncated CCN variants, their
potential regulatory functions have only recently begun to
be widely accepted. The report of CCN1(cyr61) intron 3
retention in breast cancer cells now confirms that, in
addition to well documented post-translational processing
of full length CCN proteins, alternative splicing is to be
regarded as another effective way to generate CCN
variants. These observations add to a previous bulk of
evidence that support the existence of alternative splicing
for other CCN genes. It has become clearly evident that we
need to recognize these mechanisms as a means to increase
the biological diversity of CCN proteins.
Keywords CCN1.CCN2.CCN3.CCN4.CCN5.
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Introduction
The production of CCN proteins lacking one or more of
the four structural modules (IGFBP, VWC, TSP and CT)
that constitute the prototypic CCN protein (Bork 1993;
Holbourn et al. 2008) has already been discussed (Perbal
2001, 2004; Planque and Perbal 2003).
Aside from the natural CCN5 protein that does not
contain a CT domain (Perbal 2001), several other examples
of truncated CCN proteins were identified in biological
fluids, cell culture lysates, cell culture medium, and normal
or tumor tissues (Perbal 2001, 2006; Leask and Abraham
2006; Holbourn et al. 2008).
In the case of CCN2, the production of short variants in
pig uterine flushings was hypothesized to result from
proteolytic digestion of the full length protein (Brigstock
et al. 1997). Indeed, inter-domain regions that show much
less organization than the modules themselves (Holbourn et
al. 2008) may be the target for proteolytic activity as shown
by the cleavage of CCN2 by the MMP2 metalloproteinase
at the junction between VWC and TSP1 modules (Dean et
al. 2007).
A truncated CCN3 variant deprived of both the IGFBP
domain and the signal peptide that drives secretion of the
CCN proteins (Joliot et al. 1992; Perbal 2001, 2004) was
expressed in nephroblastoma tumor cells, because of
myeloblastosis associated virus (MAV) insertional muta-
genesis in the genome of the blastemal target chicken cells
(Li et al. 2006).
CCN3 truncated isoforms that are deprived of the IGFBP
and VWC modules and contain only the last two C-terminal
modules (TSP1 and CT) were identified in most cultured
cells and tissues which also express the full length protein
(Perbal 1999, 2006; Su et al. 2001; Kyurkchiev et al. 2004;
Bleau et al. 2007; Vallacchi et al. 2008).
N-terminal sequencing of the truncated CCN3 protein
that is contained in the cell culture medium of insect cells
infected with a recombinant CCN3 baculoviral vector
(Perbal et al. 1999) established that it was generated by a
proteolytic cleavage occurring between domain II (VWC)
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cleavage site was found to be identical to that used in the
case of CCN2 , we suggested that a common specific
protease might be involved in the processing of CCN
proteins which generated these variants.
Production of CCN variants via alternative splicing
The production of rearranged CCN variants as a result of
alternative splicing has also been documented for many
times over several years.
Indeed, a CCN4 protein lacking the VWC module II
(WISP1v) was detected in scirrhous gastric carcinoma cells.
This variant is encoded by a 840 nucleotide alternatively
spliced mRNA species, missing the 260 nucleotides of exon
3 that encode VWC module sequences in the wild type
mRNA species (Tanaka et al. 2001).
Both a similarly spliced message and rearranged variant
CCN4 protein were detected in invasive cholangio-
carcinoma (Tanaka et al. 2003)a n di nt h eh u m a n
chondrosarcoma-derived chondrocytic cells HCS-2/8
(Yanagita et al. 2007). Interestingly, another spliced variant
expressed in these cells was found to encode a single
IGFBP module in which eight authentic aminoacids at the
C-terminus were replaced by 14 other residues (Yanagita et
al. 2007).
In addition to the expected full length transcript of
WISP1/CCN4 (1,204 bp), two shorter transcripts of 943 bp
and 750 bp were identified in the human hepatoma HuH-6
and HA22T/VGH cell lines (Cervello et al. 2004).
Sequence analysis of the purified 943-bp fragment revealed
that this variant lacks exon 3. Since the joining of exons 2
and 4 did not result in any reading frame shift, the variant
mRNA species also encoded a CCN4 protein lacking the
VWC module as previously described by Tanaka et al.
(2001, 2003)
Exons 3 and 4 were not contained in the CCN4 750-bp
spliced variant, and the frameshift that was created by the
joining of exons 2 and 5 in this RNA resulted into a
premature translation arrest 38 residues downstream. As a
consequence, the CCN4 variant protein expressed by this
spliced message encoded only the IGFBP module.
A longer CCN4 transcript containing an insertion of
64 bp between exons 3 and 4 was detected In HuH-6 and
HuH-7 human hepatoma cells. The insertion of this short
stretch caused a frameshift at residue 197 that resulted in a
premature translation stop 22 residues downstream. As a
consequence, a half CCN4 protein containing only the two
N-proximal IGFBP and VWC domains, was encoded by
this spliced mRNA species.
The first evidence suggesting the existence of CCN1
(cyr61) alternatively spliced messages was obtained in my
laboratory in the course of a study aimed at identifying
the chromosomal localization and expression of CCN1
in human neuroblastoma and glioblastoma cell lines
(Martinerie et al. 1997). Because the full length cDNA
clone mapped only one chromosomal location at 1p22-p31,
we proposed that the additional 3.5 kb CCN1 mRNA
species that was detected in a few cell lines in addition to
the “canonical” 2.5 kb mRNA likely corresponded to an
alternatively spliced message.
Since the focus of our studies was on the CCN3 gene
and protein, we did not pursue the identification of this
additional mRNA species.
A few years later, another example of an alternatively
spliced CCN1 mRNAs species was documented in the case
of serum-induced normal human fibroblasts, which were
shown to express a CCN1 message in which an in frame
deletion within exon 4 resulted in the production of a
CCN1 protein deprived of the TSP1 module (Leng et al.
2002).
The results that have now been reported by Hirschfeld et
al. (2009) confirm the existence of alternatively spliced
CCN1 mRNA species. Interestingly, the new message that
is identified in human breast cancer cell lines resulted from
retention of the 131 nucleotide intron 3 that separates the
exons encoding the VWC and TSP1 domains of CCN
proteins. Since this intron contains two stop codons, the
authors propose that the alternatively spliced message does
not encode a full length protein.
The organization of the various alternatively spliced
CCN mRNAs identified thus far is depicted in Fig. 1.
In the case of CCN3, several observations suggested that
variant CCN3 proteins might be produced in a regulated
way in both normal and pathological conditions.
Large amounts of a CCN3 32–38 kDa doublet were
detected in the brain lysates of adult rats in which small
amounts of the full length CCN3 protein were detected (Su
et al. 2001). Since these short variants were detected by the
K19M antibody— that was raised against the C-terminal
end of CCN3—we assumed that they were composed of the
two last domains (TSP1 and CT) and that they might be
generated through alternative splicing.
In transfected glioma cells producing exogenous CCN3,
a large amount of a half CCN3 protein was also detected in
the cytoplasmic fraction in addition to the truncated form
that is usually secreted in the culture medium of cells
producing CCN3 (Kyurkchiev et al. 2004).
Although we did not investigate the mechanisms leading
to the production of the intracellular variant CCN3 species,
all these findings suggested the existence of two CCN3
variant species that might result from two different
mechanisms: post-translational processing of the secreted
full length protein and alternative splicing leading to the
intracellular short species.
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recently identified CCN3 variant proteins that most likely
result from alternative splicing. In addition to the full length
CCN3 protein, Wilm’s tumors and normal human embry-
onic kidneys also expressed a CCN3 variant that was
deprived of the TSP1 domain (Subramaniam et al. 2008).
Also, 50% of Ewing’s tumor cells were found to express a
truncated CCN3 protein species lacking the VWC module
(Perbal et al. Submitted).
Biological significance of CCN alternative splicing
As previously discussed (Perbal 2001, 2004) the multi-
modular structure of the CCN proteins raises an interesting
question as to the contribution of each module to the
biological function(s) of the fully assembled protein. Either
the activities of each module sum up or they confer on the
whole protein specific functions that might substitute or add
to the function of the individual modules.
The present consensus is to view the biological
properties of the various CCN proteins as the result of both
individual module activities and functional interactions
between different modules (Leask and Abraham 2006;
Yeger and Perbal 2007; Irvine et al. 2008).
In view of the complex array of regulatory factors and
receptors that physically interact with CCN proteins, the
production of variants deprived of one or more elementary
module is expected to have profound biological effects. Not
only can variant CCNs titrate receptors and other partners
interacting with each individual module, and thereby
interfere with biological activity of the full length proteins,
but also, the absence of a single module might induce
conformational changes that could potentially modulate,
either positively or negatively, the intrisic biochemical
functions of the resulting CCN protein.
Various biological activities were assigned to the CCN
variants. The amino-proximal half of CCN2 (which contains
only the IGFBP and VWC domains) was reported to be an
effective surrogate biomarker for fibrosis (Leask et al. 2009)
and to mediate both myofibroblast differentiation and
collagen synthesis whereas the C-terminal half (composed
of the TSP1 and CT domains) mediated fibroblast prolif-
eration (Grotendorst and Duncan 2005). More recently, the
recombinant IGFBP and VWC modules were reported to
display stronger binding to aggrecan compared to recom-
binant TSP1 and CT modules (Aoyama et al. 2009).
In the case of CCN1, a mutant lacking the CT domain
was unable to promote cell adhesion but had conserved the
chemotactic and growth-factor promoting activities of the
full CCN1 protein (Grzeszkiewicz et al. 2001)
The amino-truncated version of CCN3 (containing the three
first modules) that was cloned from MAV-induced nephro-
blastoma exhibited transforming properties in chicken embryo
fibroblasts whereas, the full length CCN3 showed growth
inhibitory effect (Joliot et al. 1992; Planque et al. 2006).
Fig. 1 Schematic organization of the various CCN spliced variants
which have been described thus far. The prototypic structure of the
CCN proteins (except fro CCN5 lacking CT) is represented on the top,
with the five exons that encodes, the signal peptide (SP) and the Von
Willebrand (VWC), thrombospondin (TSP1) and Cterminal (CT)
domains (see Holbourn et al. 2008). Alternative splicing leading to
variant proteins has been identified for CCN1 CCN4, CCN3. In the
case of ccn1 and ccn4, the structure of the alternatively spliced
messages has been established. Variant proteins resulting from
alternative splicing have been identified in scirrhous gastric carcinoma
(a), cholangiocarcinoma (b), HCS-2⁄8 human chondrosarcoma-derived
chondrocytic cells (c), human hepatoma cells (d) Ewing’s tumors (e),
human fibroblasts (f), Wilm’s tumors and normal human embryonic
kidneys (g), human breast tumors (h). See text for details
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properties, it is surprising that neither Hirschfeld and
colleagues, nor the reviewers who evaluated their manu-
script, considered the possibility that the truncated protein
likely expressed from the CCN1 mRNA species which
retain intron3—as stated by the authors themselves—might
play a critical role in the breast cancer cells that contains
this spliced variant. The use of domain specific CCN1
antibodies that are available would have permitted to
address this important question. This is especially critical
in the context of this work, since the authors reported exon
3 skipping as a way to produce the full length active CCN1
protein (Hirschfeld et al. 2009).
In other words, the strong correlation that was observed
between the intron 3 skipping and the invasive breast
cancer phenotype might have resulted from the production
of a full-length CCN1 in these cells, whereas in non-
cancerous tissues, only the amino-proximal half CCN1 was
expressed.
These authors also report that the switch from intron
retention to intron skipping was induced by hypoxia.
This observation is in line with other results showing
that alternative splicing of CCN mRNAs is tightly regulated
and might affect the tumorigenic potential of cancer cells.
Hence, the use of domain-specific antibodies (Lazar et
al. 2007) allowed us to establish that CCN3 variants lacking
the TSP1 domain were expressed in Wilm’s tumors and that
in normal kidneys, the production of CCN3 lacking the
TSP1 domain is developmentally regulated (Subramaniam
et al. 2008).
Furthermore, we established that in the case of Ewing’s
tumors, the increased level of variant CCN3 in tumor cells
reduces their tumorigenic potential, and results in better
outcome.
Conclusion
The existence of alternative splicing leading to the
production of variant CCN proteins is well documented
and should be regarded as a means to increasing the
biological functions of this fascinating family of proteins.
Whether the variant forms that were detected in normal
and pathological conditions antagonize or synergize the
functions of full length CCN proteins remains to be
clarified. In some cases, the biological activities of variant
proteins were associated with particular phenotypes, espe-
cially in the tumor cells in which these variants were
identified. However, in other cases the origin of the variants
is not clearly established even though it is highly probable
that alternative splicing is responsible for their production.
When we first established that CCN3 was involved in
the development of the human brain (Su et al. 2001), we
used the K19M polyclonal antipeptide that is directed
against the C-terminal end of CCN3 (Chevalier et al. 1998).
As a consequence, immunocytochemistry experiments
performed with this antibody did not permit us to
distinguish between a positive staining due to the presence
of a full-length or an amino-truncated CCN3 protein.
Neither was the K19M antibody able to identify the variant
forms lacking one particular domain. Only the detection of
large quantities of a low molecular weight CCN3 variant in
rat brain lysates (Su et al. 2001) raised the possibility that
alternative splicing was involved and that the short amino-
truncated CCN3 might play a critical role in this tissue at
this particular developmental stage.
The recent results that we have obtained in the course of
study performed with Ewing’s tumors and Wilm’s tumors,
established that domain-specific antibodies such as those
we derived for CCN3 are invaluable tools to identify all the
CCN isoforms contained in cells and tissues.
The existence of variants generated by both posttransla-
tional processing and alternative splicing can no longer be
ignored by the scientific community.
Future progress and understanding of the role of CCN
proteins in normal and pathological conditions will rely on
the thorough characterization of all isoforms that requires
the use of appropriate biological tools.
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